[go: up one dir, main page]

EP1809324A4 - METHODS OF TREATING OR PREVENTING LYMPHOPROLIFERATIVE DISORDERS ASSOCIATED WITH VIRUSES - Google Patents

METHODS OF TREATING OR PREVENTING LYMPHOPROLIFERATIVE DISORDERS ASSOCIATED WITH VIRUSES

Info

Publication number
EP1809324A4
EP1809324A4 EP05810033A EP05810033A EP1809324A4 EP 1809324 A4 EP1809324 A4 EP 1809324A4 EP 05810033 A EP05810033 A EP 05810033A EP 05810033 A EP05810033 A EP 05810033A EP 1809324 A4 EP1809324 A4 EP 1809324A4
Authority
EP
European Patent Office
Prior art keywords
viruses
treating
methods
disorders associated
lymphoproliferative disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05810033A
Other languages
German (de)
French (fr)
Other versions
EP1809324A2 (en
Inventor
Robert A Baiocchi
Michael A Caligiuri
Anne M Vanbuskirk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State University Research Foundation
Original Assignee
Ohio State University Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State University Research Foundation filed Critical Ohio State University Research Foundation
Publication of EP1809324A2 publication Critical patent/EP1809324A2/en
Publication of EP1809324A4 publication Critical patent/EP1809324A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP05810033A 2004-10-13 2005-10-12 METHODS OF TREATING OR PREVENTING LYMPHOPROLIFERATIVE DISORDERS ASSOCIATED WITH VIRUSES Withdrawn EP1809324A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61845804P 2004-10-13 2004-10-13
PCT/US2005/036613 WO2006044433A2 (en) 2004-10-13 2005-10-12 Methods to treat or prevent viral-associated lymphoproliferative disorders

Publications (2)

Publication Number Publication Date
EP1809324A2 EP1809324A2 (en) 2007-07-25
EP1809324A4 true EP1809324A4 (en) 2009-02-25

Family

ID=36203475

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05810033A Withdrawn EP1809324A4 (en) 2004-10-13 2005-10-12 METHODS OF TREATING OR PREVENTING LYMPHOPROLIFERATIVE DISORDERS ASSOCIATED WITH VIRUSES

Country Status (4)

Country Link
US (1) US20090004182A1 (en)
EP (1) EP1809324A4 (en)
JP (1) JP5481028B2 (en)
WO (1) WO2006044433A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103119066B (en) * 2010-08-30 2016-04-20 独立行政法人理化学研究所 Compound having activity of inhibiting TGF-β receptor activation, screening method for the compound, and composition for preventing or treating diseases caused by hepatitis C virus
US20150056199A1 (en) 2013-08-22 2015-02-26 Acceleron Pharma, Inc. Tgf-beta receptor type ii variants and uses thereof
US10882903B2 (en) * 2015-05-18 2021-01-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for treating an alphavirus infection
AU2016301380B2 (en) 2015-08-04 2021-07-01 Acceleron Pharma Inc. Methods for treating myeloproliferative disorders
EP4241848A3 (en) 2017-05-04 2023-11-01 Acceleron Pharma Inc. Tgf-beta receptor type ii fusion proteins and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066631A1 (en) * 1999-04-30 2000-11-09 Cambridge Antibody Technology Limited SPECIFIC ANTIBODIES AND ANTIBODY FRAGMENTS FOR TGFβ¿1?

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705609A (en) * 1988-06-28 1998-01-06 La Jolla Cancer Research Foundation Decorin fragments inhibiting cell regulatory factors
US5583103A (en) * 1988-06-28 1996-12-10 La Jolla Cancer Research Foundation Inhibition of transforming growth factor beta activity
FI906411A7 (en) * 1988-06-28 1990-12-27 La Jolla Cancer Res Foundation Inhibition of cell proliferation with Decorin
US5654270A (en) * 1988-06-28 1997-08-05 La Jolla Cancer Research Foundation Use of fibromodulin to prevent or reduce dermal scarring
US5571714A (en) * 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
US6008011A (en) * 1991-10-31 1999-12-28 Whitehead Institute For Biomedical Research TGF-β type II receptor cDNAs
JP4124815B2 (en) * 1991-10-31 2008-07-23 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ TGF-β type receptor cDNA and use thereof
GB9205800D0 (en) * 1992-03-17 1992-04-29 British Tech Group Treatment of fibrotic disorders
US5869462A (en) * 1992-09-10 1999-02-09 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
US5821234A (en) * 1992-09-10 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
JPH08504763A (en) * 1992-10-29 1996-05-21 セルトリックス ファーマシューティカルズ，インコーポレイテッド Use of TGF-β receptor fragment as a therapeutic agent
US5830847A (en) * 1992-10-30 1998-11-03 Hsc Research & Development Limited Partnership Soluble TGF-β-binding endoglin polypeptides and homodimers
AU6984594A (en) * 1993-06-15 1995-01-17 Hun Taeg Chung Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof
JPH09512910A (en) * 1994-05-04 1997-12-22 マウント・サイナイ・ホスピタル・コーポレイション TGF-β superfamily cytokine modulators and assay methods thereof
US5772995A (en) * 1994-07-18 1998-06-30 Sidney Kimmel Cancer Center Compositions and methods for enhanced tumor cell immunity in vivo
CA2156767A1 (en) * 1994-08-25 1996-02-26 Kenichi Matsunaga Binding agent for growth factor
US5834248A (en) * 1995-02-10 1998-11-10 Millennium Pharmaceuticals Inc. Compositions and methods using rchd534, a gene uregulated by shear stress
US5824655A (en) * 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
US5807708A (en) * 1996-07-30 1998-09-15 Millennium Pharmaceuticals, Inc. Conservin nucleic acid molecules and compositions
US5948639A (en) * 1997-04-10 1999-09-07 Millennium Pharmaceuticals, Inc. TGF-β pathway genes
JPH10295381A (en) * 1997-04-23 1998-11-10 Seibutsu Bunshi Kogaku Kenkyusho:Kk Signal transfer factor and gene encoding the same
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
US7173002B2 (en) * 2001-04-24 2007-02-06 Mcgill University 150 KDA TGF-B1 accessory receptor acts a negative modulator of TGF-B signaling
US20030180301A1 (en) * 2002-01-22 2003-09-25 Shaf Keshavjee Use of TGF-beta antagonists to treat or to prevent chronic transplant rejection
AU2004299670B2 (en) * 2003-12-19 2010-04-22 Antisense Pharma Gmbh Combination therapy associating a TGF-beta antagonist with a chemotherapeutic agent

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066631A1 (en) * 1999-04-30 2000-11-09 Cambridge Antibody Technology Limited SPECIFIC ANTIBODIES AND ANTIBODY FRAGMENTS FOR TGFβ¿1?

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Lymphoproliferative disorders", WIKIPEDIA, 24 September 2013 (2013-09-24), XP055080745, Retrieved from the Internet <URL:http://en.wikipedia.org/wiki/Lymphoproliferative_disorders> [retrieved on 20130924] *
C. M. BOLLARD ET AL: "Adapting a transforming growth factor beta -related tumor protection strategy to enhance antitumor immunity", BLOOD, vol. 99, no. 9, 1 May 2002 (2002-05-01), pages 3179 - 3187, XP055080715, ISSN: 0006-4971, DOI: 10.1182/blood.V99.9.3179 *
DIERKSHEIDE JULIE E ET AL: "IFN-gamma gene polymorphisms associate with development of EBV+ lymphoproliferative disease in hu PBL-SCID mice.", BLOOD 15 FEB 2005, vol. 105, no. 4, 15 February 2005 (2005-02-15), pages 1558 - 1565, XP002509859, ISSN: 0006-4971 *
LAZDINS J K ET AL: "In vitro effect of transforming growth factor-beta on progression of HIV-1 infection in primary mononuclear phagocytes.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 AUG 1991, vol. 147, no. 4, 15 August 1991 (1991-08-15), pages 1201 - 1207, XP002509862, ISSN: 0022-1767 *
PETERSON P K ET AL: "Cocaine amplifies HIV-1 replication in cytomegalovirus-stimulated peripheral blood mononuclear cell cocultures.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 JUL 1992, vol. 149, no. 2, 15 July 1992 (1992-07-15), pages 676 - 680, XP002509860, ISSN: 0022-1767 *
PETERSON P K ET AL: "Cocaine potentiates HIV-1 replication in human peripheral blood mononuclear cell cocultures. Involvement of transforming growth factor-beta.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 JAN 1991, vol. 146, no. 1, 1 January 1991 (1991-01-01), pages 81 - 84, XP002509861, ISSN: 0022-1767 *
ROONEY ET AL: "Immunotherapy for Hodgkin's disease.", ANNALS OF HEMATOLOGY, vol. 81 Suppl 2, 1 January 2002 (2002-01-01), pages S39 - S42, XP055080709, ISSN: 0939-5555 *
VANBUSKIRK A M ET AL: "A gene polymorphism associated with posttransplant lymphoproliferative disorder.", TRANSPLANTATION PROCEEDINGS 2001 FEB-MAR LNKD- PUBMED:11267533, vol. 33, no. 1-2, February 2001 (2001-02-01), pages 1834, ISSN: 0041-1345 *
WOJTOWICZ-PRAGA S: "REVERSAL OF TUMOR-INDUCED IMMUNOSUPPRESSION BY TGF-BETA INHIBITORS", INVESTIGATIONAL NEW DRUGS, MARTINUS NIJHOFF PUBLISHERS, BOSTON, US, vol. 21, no. 1, 1 February 2003 (2003-02-01), pages 21 - 32, XP008035079, ISSN: 0167-6997, DOI: 10.1023/A:1022951824806 *

Also Published As

Publication number Publication date
EP1809324A2 (en) 2007-07-25
JP5481028B2 (en) 2014-04-23
WO2006044433A2 (en) 2006-04-27
US20090004182A1 (en) 2009-01-01
JP2008515983A (en) 2008-05-15
WO2006044433A3 (en) 2007-07-12

Similar Documents

Publication Publication Date Title
EP2036294A4 (en) RESTRICTION AND PREVENTION OF MATTERING ATTEMPTS FROM VIRUS ATTACKS AND MALWARE SOFTWARE
NO20091183L (en) Derivatives of 4- (N-azacycloalkyl) -anilides, processes for the preparation of such compounds, compositions comprising such compounds and the use of such compounds for the prevention or treatment of disease
EP2152261A4 (en) TREATMENT OF INJURIES CAUSED BY VIRUSES
BRPI0813436A2 (en) PARTICULATES OF (4,6-BIS (DIMETHYLAMINO) -2- (4- (4- (TRIFLUOROMETIL) BENZAMIDE) -BENZIL) PYRIMINDIN-5-IL} ACETIC, METHODS FOR TREATMENT, PREVENTION OR IMPROVEMENT OR MORE SYMPTOMS OF A CRTH2-MEDIATED DISEASE, EOSINOPHILIA-RELATED DISEASE, A BASOPHYL-RELATED DISEASE, AND A PROCESS FOR THE PREPARATION OF PARTICULATES.
EP2063882A4 (en) KINASE INHIBITORS FOR THE PREVENTION OR TREATMENT OF INFECTION
LT2878297T (en) MEDICINES FOR THE TREATMENT OR PREVENTION OF FIBROSIC DISEASES
EP1927363A4 (en) EXTRACT FOR PREVENTING OR TREATING THROMBOTIC DISORDERS
EP1809369A4 (en) MEDICAL DEVICES FOR THE DETECTION, PREVENTION AND / OR TREATMENT OF NEUROLOGICAL DISORDERS, AND ASSOCIATED METHODS
EP2203168A4 (en) METHODS OF TREATING INFECTION WITH FLAVIVIRIDAE FAMILY VIRUSES AND COMPOSITIONS FOR TREATING INFECTION WITH FLAVIVIRIDAE FAMILY VIRUSES
EP1812068A4 (en) METHODS FOR PREVENTING AND TREATING RSV INFECTIONS AND ASSOCIATED DISEASES
EP2118074A4 (en) COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES
ATE443769T1 (en) VACCINE FOR THE PREVENTION AND TREATMENT OF HIV INFECTION
EP2001516A4 (en) VACCINES FOR VIRUSES CAUSING PERSISTENT OR LATENT INFECTIONS
ATE512948T1 (en) BIPHENYL-SULFONYL AND PHENYL-HETEROARYL-SULFONYL MODULATORS OF THE HISTAMINE H3 RECEPTOR FOR THE TREATMENT OF RELATED DISEASES
EP2136814A4 (en) MEDICATION KITS AND FORMULATIONS FOR PREVENTING, TREATING OR REDUCING SECONDARY FRACTURES AFTER ANOTHER FRACTURE
EP2646043A4 (en) NEW CICLOSPORINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTION
EP1865972A4 (en) TREATMENT OR PREVENTION OF CANCER AND PRECANCEROUS DISORDERS
BR112015000685A2 (en) method for identifying clinical risk in a patient possessing or suspected of having an influenza infection, method for identifying influenza or viral pneumonia in a patient, kit, method for assessing the effectiveness of an agent for treating influenza and for reduce the severity of the disease in an individual exposed to an influenza virus.
EP1786428A4 (en) PDE5 INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CARDIAC DISORDERS
BRPI0718469A2 (en) USE OF AN INTERLEUCIN 1 ANTAGONIST (IL-1), METHOD FOR TREATING, INHIBITING OR IMPROVING PSEUDOGOTA, USE OF ONE OR MORE THERAPEUTIC AGENTS, AND, PRODUCT.
PT1299395E (en) OXAZINOQUINOLONES UTEIS FOR THE TREATMENT OF INFECTIONS CAUSED BY VIRUSES
CL2004000261A1 (en) PROCEDURE FOR THE ELIMINATION OF VIRUSES IN THERAPEUTIC APPLICATION FIBRINOGEN SOLUTIONS.
EP1814854A4 (en) CATIONIC CERAMIDES AND THEIR ANALOGUES, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF CANCER
EP1809324A4 (en) METHODS OF TREATING OR PREVENTING LYMPHOPROLIFERATIVE DISORDERS ASSOCIATED WITH VIRUSES
DK1993585T3 (en) Use of the long pentraxin PTX3 for the prevention or treatment of viral diseases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070504

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

R17D Deferred search report published (corrected)

Effective date: 20070712

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/395 20060101AFI20070724BHEP

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/22 20060101AFI20090115BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20090123

17Q First examination report despatched

Effective date: 20090603

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20151111